Edition:
United States

Allergan plc (AGN)

AGN on New York Consolidated

230.31USD
30 Sep 2016
Change (% chg)

$-0.49 (-0.21%)
Prev Close
$230.80
Open
$231.23
Day's High
$232.22
Day's Low
$228.68
Volume
4,170,581
Avg. Vol
3,181,245
52-wk High
$322.68
52-wk Low
$195.50

Latest Key Developments (Source: Significant Developments)

Allergan says supplemental NDA for 72 mcg Linaclotide accepted for FDA review
Thursday, 9 Jun 2016 08:01am EDT 

Allergan Plc : FDA prescription drug user fee act (PDUFA) target action date is expected to occur in early 2017 . FDA accepted for review SNDA for 72 mcg dose of Linaclotide for use in treatment of adults with chronic idiopathic constipation .Ironwood and Allergan announce supplemental new drug application for 72 mcg Linaclotide in chronic idiopathic constipation has been accepted for FDA review.  Full Article

Monosol Rx wins patent infringement suit against Par pharma, Watson pharma
Tuesday, 7 Jun 2016 11:04am EDT 

Monosol Rx : Monosol Rx Wins Patent Infringement Suit Against Par Pharmaceutical And Watson Pharmaceuticals Related To Suboxone Sublingual Film .Ruling Expected To Prevent Generic Buprenorphine, Naloxone Film Products From Entering Market Prior To The Patent’S Expiration In 2024.  Full Article

Valeant Pharmaceuticals Q1 adjusted non-gaap EPS $1.27
Tuesday, 7 Jun 2016 06:11am EDT 

Valeant Pharmaceuticals International Inc : Updating its full year 2016 guidance . FY adjusted ebitda (non-gaap) is expected to be in range of $4.80 - $4.95 billion . FY 2016 earnings per share view $8.46, revenue view $10.86 billion -- Thomson Reuters I/B/E/S . "We have made progress toward stabilizing organization over past few months" . While we recognize that we did not meet timeline for filing Q1 results, with filing expected this week, we will be current in our financial reporting . "Expect to file our financial results in a timely manner going forward" . "There are some challenges to work through in certain business operations in 2016, such as our u.s. Dermatology unit" . Full year 2016 total revenue guidance updated from previous guidance of $11.0 - $11.2 billion . Full year 2016 adjusted eps (non-gaap) guidance updated from previous guidance of $8.50 - $9 .50 . Q1's results reflect, in part, impact of "significant disruption" this organization has faced over past nine months . "There are some challenges to work through in certain business operations in 2016" . "Majority of our businesses are performing according to expectations" . Valeant pharmaceuticals reports first quarter 2016 financial results . Sees FY 2016 adjusted non-gaap earnings per share $6.60 to $7.00 . Q1 adjusted non-gaap earnings per share $1.27 . Q1 gaap loss per share $1.08 . Sees FY 2016 revenue $9.9 billion to $10.1 billion.  Full Article

Allergan CEO to CNBC: "Don't know exactly" how large Icahn's position in the company is
Monday, 6 Jun 2016 10:52am EDT 

: Allergan CEO to CNBC: "Don't know exactly" how large Icahn's position in the company is . Allergan CEO to CNBC: Will begin to buyback shares immediately upon close of Teva deal, which is expected at end of this month Further company coverage: [AGN.N] (Bengaluru Newsroom) ((+1 646 223 8780;)).  Full Article

Allergan announces FDA approval of byvalson
Monday, 6 Jun 2016 07:31am EDT 

Allergan Plc : Allergan expects byvalson to be available in 2nd half of 2016. . Approval of byvalson 5 mg/ 80 mg tablets, by U.S. food and drug administration (FDA) for treatment of hypertension to lower blood pressure .Allergan announces FDA approval of byvalson(tm) (nebivolol and valsartan).  Full Article

Allergan receives FDA approval to market Juvéderm Volbella XC
Wednesday, 1 Jun 2016 07:31am EDT 

Allergan Plc : Received approval from U.S. Food And Drug Administration (FDA) to market Juvéderm Volbella XC .Juvéderm Volbella XC approved by FDA for use in lips and perioral rhytids.  Full Article

Allergan acknowledges Carl Icahn investment - CNBC
Tuesday, 31 May 2016 10:05am EDT 

: Allergan acknowledges Carl Icahn investment - CNBC . Allergan says it does not believe Icahn investment was made for purpose of control of co - CNBC Further company coverage: [AGN.N] (Bengaluru Newsroom) ((+1 646 223 8780;)).  Full Article

Valeant Pharmaceuticals names Sam Eldessouky SVP and corporate controller
Thursday, 26 May 2016 07:00am EDT 

Valeant Pharmaceuticals International Inc - : Valeant Pharmaceuticals names Sam Eldessouky senior vice president and corporate controller . Eldessouky joins Valeant from Tyco International PLC, where he served as senior vice president .Valeant Pharmaceuticals names Sam Eldessouky senior vice president and corporate controller.  Full Article

Allergan announces FDA acceptance of NDA filing for oxymetazoline hci cream 1.0%
Tuesday, 24 May 2016 07:31am EDT 

Allergan Plc : Allergan announces FDA acceptance of NDA filing for oxymetazoline hci cream 1.0% .Says expects PDUFA date in first half 2017.  Full Article

Allergan's botox wins Japanese approval to treat crow's feet lines
Monday, 23 May 2016 04:30pm EDT 

Allergan Plc : Allergan's botox vista® (botulinum toxin type a) receives national marketing authorisation in japan for treatment of crow's feet lines in adult patients .Japanese ministry of health, labour and welfare has approved an additional use for botox vista as a treatment for crow's feet lines.  Full Article

BRIEF-Allergan issues statement on Namenda XR patent litigation following announcement of ANDA approvals

* Company has settled with all other Namenda XR ANDA defendants, including Lupin Limited and Lupin Pharmaceuticals Inc